O'Donnell, Chris Genomics and Nucleic Acid Therapeutics in Prevention & Treatment of Cardiometabolic Disease: A View from Pharma.

Abstract

Presentation will include recent developments in human genetics and genomics of CVD and focus on nucleic acid therapies. WIll not cover any undisclosed therapies and will not promote novartis therapies that are discussed. Gene editing will be mentioned as one option in nucleic acid therapy but not discussed in any detail.
Overview:
Role of human genetics / genomics in etiology of risk factors and disease and discovery of cardio-metabolic disease biomarkers and targets
Genetic / genomic targets for cardio-metabolic disease and options for nucleic acid-based therapies for prevention, pre-emption and treatment of disease
Strengths, Weaknesses, Opportunies, Threats: Lessons from ASO and siRNA trials
Gaps and opportunities to leverage genetics and genomics in future trials for treatment and prevention

Item Type:	Article
Date Deposited:	16 Oct 2024 00:45
Last Modified:	16 Oct 2024 00:45
URI:	https://oak.novartis.com/id/eprint/53025